Home
About Us
FAQ
Contact Us
Media Tools
ExpertConnect App
MyExpertNet
University Partners
Becoming a Partner
Key Organizations
Search Assistance
Help
Expert Profile
Share
QR code
Edit Profile
Daniel Araujo
Clin Aso Prof
MD-HEMATOLOGY-ONCOLOGY | COLLEGE-MEDICINE
View:
Select
All (all in one)
Research Terms and Keywords
Publications
Network
Websites
Contact
All
Research
Publications
Network
Websites
Contact
Research Terms & Keywords
Research Terms
Hematology
Research Projects
Ends
Title
02-2026
PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)
PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)
NATL INST OF HLTH NC
02-2026
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
NATL INST OF HLTH NC
02-2026
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
NRG ONCOLOGY FOU
02-2026
A PHASE II STUDY OF DOSE-DENSE GEMCITABINE PLUS CISPLATIN (DDGC) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE RESPONSE (DDR) GENE ALTERATIONS
A PHASE II STUDY OF DOSE-DENSE GEMCITABINE PLUS CISPLATIN (DDGC) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE RESPONSE (DDR) GENE ALTERATIONS
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY
02-2026
A PHASE II STUDY OF DOSE-DENSE GEMCITABINE PLUS CISPLATIN (DDGC) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE RESPONSE (DDR) GENE ALTERATIONS
A PHASE II STUDY OF DOSE-DENSE GEMCITABINE PLUS CISPLATIN (DDGC) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE RESPONSE (DDR) GENE ALTERATIONS
NATL INST OF HLTH NC
Publications
OpenAlex
Search Engines
Data import pending. See our
OpenAlex FAQ
for more about this data.
Search Google Scholar for Daniel Araujo
Co-Investigator Network
Paul Crispen
Clinical Professor, Pete and Carolyn Newsome Urologic Oncology Professorship, David A. Cofrin Endowed Chair Of Urologic Oncology, and Associate Director Of Clinical Research, Uf Health Cancer Center
University of Florida
Md-Urology, College-Medicine
paul.crispen@urology.ufl.edu
Jonathan Chatzkel
Assistant Professor
University of Florida
Md-Hematology-Oncology, College-Medicine
jonathanchatzkel@ufl.edu
Inactive Expert
Brian Ramnaraign
Assistant Professor
University of Florida
Md-Urology, College-Medicine
Websites
ORCID 0000-0002-7013-5408
Search Google Scholar for Daniel Araujo
Contact Information
daniel.araujo@ufl.edu
3522737832
PO Box 100278 GAINESVILLE, FL 32610-0278
Profile QR code
What is this?
Keyword Search
Please enter valid search criteria.
Search
Centers
Experts
Projects
Speakers
Stories
Technologies
Videos
University
All Universities
Florida A&M University
Florida Atlantic University
Florida Gulf Coast University
Florida Institute of Technology
Florida International University
Florida State University
University of Central Florida
University of Florida
University of Miami
University of North Florida
University of South Florida
University of West Florida
Browse by STEM
Biotechnology
Computer Science
Energy
Engineering
Environmental Sciences
Information Science
Life Sciences
Mathematics
Medical Sciences
Military Sciences
Natural Sciences
Physical Sciences
Plant Sciences
Science
Space Sciences
Technology
Transportation
